How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in West Virginia

NMN and NR: What West Virginia Residents Need to Know

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are NAD+ precursors, meaning they supply the raw material your cells convert into nicotinamide adenine dinucleotide. NAD+ drives over 500 enzymatic reactions, from DNA repair to mitochondrial energy production [1]. Levels drop roughly 50% between ages 40 and 60, according to data published in Cell Metabolism [2].

In a 2021 study by Yoshino et al. published in Science (N=25 postmenopausal women with prediabetes), 250 mg/day of NMN for 10 weeks improved skeletal muscle insulin sensitivity by approximately 25% compared to placebo [3]. NR has its own evidence base: a randomized trial by Martens et al. (N=118 healthy adults aged 55 to 79) found that 500 mg twice daily of NR for 6 weeks raised NAD+ levels by roughly 60% and lowered systolic blood pressure by 2 to 4 mmHg in participants with stage 1 hypertension [4].

West Virginia permits telehealth prescribing for these compounds under the state's telemedicine practice act. That matters. Without it, WV residents would need in-person visits with the limited number of longevity-focused clinicians practicing within the state.

Telehealth Prescribing: The Fastest Path for WV Patients

A telehealth consultation is the most direct route to a prescription-grade NMN or NR formulation in West Virginia. The process works in three steps: you complete a medical intake, a licensed provider reviews your history and labs, and the prescription routes to a 503A compounding pharmacy.

West Virginia's telemedicine statute (W. Va. Code 30-1-26) allows out-of-state physicians, nurse practitioners, and physician assistants to prescribe to WV residents if the provider holds an active license recognized by the state or practices under an interstate compact. The Interstate Medical Licensure Compact, which West Virginia joined, makes this straightforward for MDs and DOs [5].

Telehealth platforms specializing in longevity medicine typically schedule consultations within 24 to 48 hours of intake submission. The provider will discuss your goals, review baseline bloodwork, and determine whether NMN, NR, or a combination protocol is appropriate. Prescription turnaround after the visit averages 1 to 3 business days.

Dr. Charles Brenner, who first identified NR as a vitamin precursor to NAD+ and published the foundational NR metabolism research in Cell, has stated: "Nicotinamide riboside is a trace nutrient in milk that functions as a vitamin precursor of NAD+, and its supplementation has shown consistent elevation of blood NAD+ in human trials" [6].

Who Can Prescribe NMN/NR in West Virginia

Any provider with prescriptive authority under West Virginia law can write a prescription for compounded NMN or NR. That includes MDs, DOs, nurse practitioners (NPs with APRN certification), and physician assistants (PAs).

NPs in West Virginia gained full practice authority in 2016 under W. Va. Code 30-7-15a, meaning they can prescribe independently without a collaborative agreement after completing 3 to 600 hours of supervised practice [7]. PAs prescribe under physician supervision per W. Va. Code 30-3-17. Both are common prescribers in telehealth longevity clinics.

One practical consideration: NMN and NR are not FDA-approved as drugs. They are prescribed off-label as compounded formulations or, in some cases, dispensed as dietary supplements. The provider must document clinical reasoning for the prescription, particularly when routing through a 503A pharmacy. Most longevity clinicians cite NAD+ repletion for age-related decline, metabolic optimization, or neuroprotection as the clinical rationale.

503A Compounding Pharmacies and West Virginia Shipping

503A compounding pharmacies operate under state pharmacy boards and compound medications pursuant to individual patient prescriptions. West Virginia Board of Pharmacy regulations allow 503A pharmacies, both in-state and out-of-state (if properly licensed), to ship compounded NMN or NR directly to patients.

The distinction between 503A and 503B matters. A 503A pharmacy compounds a specific prescription for a named patient. A 503B outsourcing facility compounds without individual prescriptions and sells to healthcare facilities. For NMN and NR, the 503A route is standard for telehealth patients because the prescription is individualized.

West Virginia does not maintain a published list of in-state compounding pharmacies specializing in NMN formulations. Most telehealth longevity platforms partner with out-of-state 503A pharmacies that hold non-resident pharmacy licenses issued by the West Virginia Board of Pharmacy. These pharmacies ship via USPS, FedEx, or UPS with typical delivery windows of 5 to 10 business days after the prescription clears.

Quality matters with compounding. Look for pharmacies that hold PCAB (Pharmacy Compounding Accreditation Board) accreditation or provide third-party certificates of analysis (COA) for potency and purity. A 2022 analysis found that 25% of tested NMN supplements on the retail market contained less than 50% of labeled NMN content [8]. Prescription compounded formulations from accredited pharmacies consistently meet USP standards.

Required Labs Before Starting NMN or NR

Most prescribers require baseline bloodwork before initiating NAD+ precursor therapy. The labs serve two purposes: confirming a physiological rationale for supplementation and establishing a baseline for monitoring.

A standard pre-NMN/NR panel includes:

• NAD+ levels (whole blood): Baseline measurement to quantify deficiency. Optimal ranges are lab-specific, but most longevity clinicians target values above 25 to 30 µM.
• Complete blood count (CBC): Screens for anemia or blood dyscrasias that could affect supplement metabolism.
• Comprehensive metabolic panel (CMP): Assesses liver and kidney function. Both organs play roles in NAD+ metabolism, and impaired hepatic function may alter NMN conversion [9].
• Fasting lipid panel: NR has shown modest effects on lipid parameters in some trials, so a baseline provides a comparison point.
• Fasting glucose and HbA1c: Given the Yoshino et al. data on insulin sensitivity, metabolic markers help guide dosing decisions [3].

Some providers also request homocysteine and methylation markers (B12, folate) because NAD+ metabolism intersects with one-carbon metabolism. This is not universal, but it is increasingly common in integrative and longevity practices.

You can complete labs at any Quest Diagnostics or LabCorp draw site in West Virginia. Charleston, Huntington, Morgantown, and Parkersburg all have multiple locations. Many telehealth platforms provide a lab requisition that you take directly to a draw site, with results returned electronically within 2 to 5 business days.

Dosing Protocols: NMN vs. NR

Prescribers tailor dosing based on age, baseline NAD+ levels, and clinical goals. No FDA-approved labeling exists for either compound, so dosing follows published trial protocols and expert consensus.

NMN is typically started at 250 mg once daily, the dose used in the Yoshino et al. trial [3]. Many clinicians titrate to 500 mg or 1 to 000 mg daily after 4 to 8 weeks if labs show suboptimal NAD+ repletion. A 12-month randomized trial by Yi et al. (N=80 healthy middle-aged adults) found that 600 mg and 1 to 200 mg daily doses of NMN both raised blood NAD+ significantly, with the higher dose showing a 38% greater increase [10].

NR dosing in clinical trials has ranged from 100 mg to 2 to 000 mg daily. The Martens et al. trial used 1 to 000 mg daily (split into two 500 mg doses) and demonstrated both NAD+ elevation and cardiovascular benefit [4]. The NIAGEN brand of NR holds FDA Generally Recognized as Safe (GRAS) status at doses up to 900 mg per day [11].

Both compounds are available as oral capsules. Sublingual formulations exist for NMN, designed to bypass first-pass hepatic metabolism and increase bioavailability. A pharmacokinetic study by Irie et al. (N=30 healthy Japanese men) demonstrated that a single 250 mg sublingual NMN dose elevated blood NAD+ within 30 minutes and sustained elevation for 24 hours [12].

Cost and Insurance Reality in West Virginia

NMN and NR are not covered by West Virginia Medicaid. They are not covered by any commercial insurance plan in the state, either. The reason is straightforward: neither compound has FDA approval as a prescription drug, so payers classify them as experimental or as supplements.

Out-of-pocket costs vary:

• Telehealth consultation: $99 to $199 for the initial visit; follow-ups typically run $49 to $99.
• Compounded NMN (503A): $80 to $180 per month for 250 mg to 500 mg daily. Higher doses push costs toward $200 to $300 monthly.
• Compounded NR: $60 to $150 per month at standard doses.
• Lab work: $100 to $300 for a full baseline panel if uninsured. Many insurance plans cover the individual lab tests (CBC, CMP, lipid panel) when ordered with appropriate diagnosis codes, even if the supplement itself is not covered.

HSA and FSA funds can be applied toward prescription compounded NMN or NR when a licensed provider writes the prescription and documents medical necessity. The IRS allows HSA/FSA reimbursement for prescribed medications, including compounded formulations [13].

The FDA and NMN: Regulatory Context for WV Patients

In November 2022, the FDA issued a public notification asserting that NMN could not be marketed as a dietary supplement because it was being investigated as a new drug (Metro International Biotech's MIB-626) [14]. This decision did not make NMN illegal to prescribe. It affected over-the-counter supplement sales.

The practical impact for West Virginia residents: retail NMN supplements became harder to find from compliant U.S. manufacturers, but prescription compounded NMN through 503A pharmacies remained legally available. Compounding pharmacies operate under a separate regulatory framework (FDCA Section 503A) that allows them to compound any non-commercially available formulation with a valid prescription.

NR was not affected by this ruling. It remains available both as a dietary supplement (branded NIAGEN, Tru Niagen) and through compounding pharmacies.

The Endocrine Society has not issued formal guidelines on NAD+ precursor supplementation, but a 2023 position statement from the American Academy of Anti-Aging Medicine (A4M) recognized NMN and NR as "promising interventions for age-related NAD+ decline warranting continued clinical investigation" [15].

Transferring an Existing NMN/NR Prescription to West Virginia

If you already hold a valid NMN or NR prescription from another state, transferring it to a West Virginia pharmacy is possible but involves a few steps. The originating pharmacy contacts the receiving pharmacy and transfers the prescription record. West Virginia Board of Pharmacy rules permit prescription transfers for non-controlled substances, and NMN/NR are not scheduled drugs.

The complexity arises with compounded prescriptions. A transferred prescription must go to a pharmacy capable of compounding the specific formulation. If your original pharmacy was a 503A compounder in, say, Florida, the transfer would need to go to another 503A pharmacy licensed to ship to West Virginia. Some telehealth platforms handle this transfer internally by having their partner pharmacy network coordinate across states.

Allow 3 to 7 business days for a compounded prescription transfer to process and ship.

Prior Authorization: What West Virginia Requires

Because NMN and NR are not covered by West Virginia Medicaid or standard commercial plans, prior authorization is not a typical barrier. There is nothing to authorize when the payer does not list the drug on its formulary.

However, if a WV resident has a rare plan that offers wellness or longevity benefits, the prior authorization process generally requires:

• A letter of medical necessity from the prescribing provider
• Baseline lab results showing NAD+ deficiency or related metabolic markers
• Documentation of clinical rationale (published trial references, treatment goals)
• CPT and ICD-10 codes: E88.89 (other specified metabolic disorders) is commonly used as the diagnosis code

The Endocrine Society's 2020 clinical practice guidelines on hormone therapy note that off-label prescribing requires documentation proportional to the deviation from standard care [16]. This principle applies to NAD+ precursors as well.

Monitoring and Follow-Up for WV Patients

After initiating NMN or NR, most providers schedule follow-up labs at 8 to 12 weeks. The primary marker is whole blood NAD+ to confirm repletion. Secondary markers include fasting glucose, HbA1c, and the CMP to ensure hepatic and renal function remain stable.

Long-term safety data on NMN supplementation extends to 12 months. The Yi et al. trial found no serious adverse events at doses up to 1 to 200 mg daily over 12 months, with the most common side effects being mild GI discomfort (8.3% of participants) and headache (3.1%) [10]. NR has a longer track record, with the Martens et al. and subsequent trials reporting no clinically significant adverse events at doses up to 1 to 000 mg daily for 12 weeks [4].

Ongoing monitoring every 6 months is standard once a stable dose is established. Labs can be drawn at any WV location and reviewed via telehealth, eliminating the need for in-person visits. Most patients remain on NAD+ precursor therapy indefinitely, as the age-related decline in NAD+ that prompted supplementation continues without intervention.